1995867-02-1
Chemical Structure
BETi-211
- CAS No.: 1995867-02-1
- Formula:C26H29N7O3
- Molecular Weight:487.55
IUPAC Name: N-(3-cyclopropyl-1-ethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-(methoxymethyl)-9H-pyrimido[4,5-b]indol-4-amine
InChIKey: IOUPQJFKVLVXRQ-UHFFFAOYSA-N
SMILES: COCC1=NC(NC2=CC(C3CC3)=NN2CC)=C4C(NC5=C4C=C(OC)C(C6=C(C)ON=C6C)=C5)=N1
Biological Activity: BETi-211 is an orally active, selective BET inhibitor with a Ki < 1 nM. BETi-211 inhibits BET function as epigenetic readers by binding to BET proteins (BRD2, BRD3, and BRD4). BETi-211 suppresses the growth of various triple-negative breast cancer (TNBC) cell lines, with an IC50 < 1 μM. BETi-211 can be utilized to synthesize PROTAC molecules designed to degrade BET proteins. BETi-211 is applicable for research into TNBC[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BETi-211 | BETi-211 is an orally active, selective BET inhibitor with a Ki < 1 nM. BETi-211 inhibits BET function as epigenetic readers by binding to BET proteins (BRD2, BRD3, and BRD4). BETi-211 suppresses the growth of various triple-negative breast cancer (TNBC) cell lines, with an IC50 < 1 μM. BETi-211 can be utilized to synthesize PROTAC molecules designed to degrade BET proteins. BETi-211 is applicable for research into TNBC. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
